Considering that the clearance of overexpressed, hyperphosphorylated and misfolded tau was mediated via TFEB activation in a mouse tauopathy model16, it is speculated that the inhibiting mTORC1 could be a potential therapeutic strategy for increasing the degradation of pathological tau species in AD. Here, MAPT is linked to tauopathy.